Skip to main content

Advertisement

SpringerLink
Log in

Tamoxifen induced-non-alcoholic steatohepatitis (NASH): Has the time come for the oncologist to be diabetologist

  • Letter to the editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Decensi A, Veronesi U: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330(7497): 932, 2005

    Google Scholar 

  2. Ahmed MH, Byrne CD, 2005 non-alcoholic steatohepatitis In: Byrne CD, Wild S, (eds) Metabolic Syndrome England Wiley & Sons Ltd pp. 279–303

    Chapter  Google Scholar 

  3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P, The natural history of non-alcoholic fatty liver disease: a population-based cohort study Gastroenterology2005; 129:113–121

    Article  PubMed  Google Scholar 

  4. Ahmed MH, Invasive and non-invasive investigations for non-alcoholic steatohepatitis: the benefit of histology Scand J Gastroenterol 2005 40(10):1260

    Article  PubMed  CAS  Google Scholar 

  5. Murata Y, Ogawa Y, Saibara T, Nishioka A, Takeuchi N, Kariya S, Onishi S, Yoshida S, Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis Oncol Rep2003; 10:97–100

    PubMed  Google Scholar 

  6. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, LIDO Study Group. Sampling variability of liver biopsy in non-alcoholic fatty liver disease Gastroenterology 2005; 128:1898–1906

    Article  PubMed  Google Scholar 

  7. Nemoto Y, Toda K, Ono M, et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice J Clin Invest 2000; 105:1819–1825

    Article  PubMed  CAS  Google Scholar 

  8. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H, The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek Sub-study Breast Cancer Res Treat 2005; 93:61–66

    Article  PubMed  CAS  Google Scholar 

  9. Wild S, Roglic G, Green A, Sicree R, King H, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27:1047–1053

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chemical Pathology Department, Southampton General Hospital, Southampton, UK

    M.H. Ahmed

  2. Department of Surgery, Queen’s Hospital, Burton on Trent, Staffordshire, UK

    K.A. Osman

  3. Chemical Pathology Department, Southampton General Hospital, Mail point 6, Level D South Academic Block, Tremona Road, SO16 6YD , Southampton , UK

    M.H. Ahmed

Authors
  1. M.H. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.A. Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M.H. Ahmed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmed, M., Osman, K. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): Has the time come for the oncologist to be diabetologist. Breast Cancer Res Treat 97, 223–224 (2006). https://doi.org/10.1007/s10549-005-9104-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-005-9104-9

Keywords

Search

Navigation